Search in:

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 12

Submit an article Journal homepage

158

Views

CrossRef citations to date

Altmetric

Reviews

Pharmacotherapy of endometrial cancer

Nicanor I Barrena Medel Columbia University College of Physicians and Surgeons, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, New York, USA; Columbia University College of Physician and Surgeons, Herbert Irving Comprehensive Cancer Center, 8th Floor, Room 838, 161 Fort Washington Avenue, New York, NY 10032, USA +1 212 305 3410; +1 212 305 3412; [email protected]; Hospital Sotero del Rio, Gynecologic Oncology Unit, Department of Obstetrics & Gynecology, Santiago, Chile

Sharmilee Bansal Columbia University College of Physicians and Surgeons, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, New York, USA

David Scott Miller University of Texas Southwestern Medical Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Dallas, Texas, USA

Jason D Wright Columbia University College of Physicians and Surgeons, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, New York, USA; Columbia University College of Physician and Surgeons, Herbert Irving Comprehensive Cancer Center, 8th Floor, Room 838, 161 Fort Washington Avenue, New York, NY 10032, USA +1 212 305 3410; +1 212 305 3412; [email protected]

Thomas J Herzog Columbia University College of Physician and Surgeons, Herbert Irving Comprehensive Cancer Center, 8th Floor, Room 838, 161 Fort Washington Avenue, New York, NY 10032, USA +1 212 305 3410; +1 212 305 3412; [email protected]

Pages 1939-1951 | Published online: 08 Jul 2009

Cite this article
https://doi.org/10.1517/14656560903061291

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

International Agency for Research on Cancer (IARC). World Cancer Report 2008. Lyon: IARC.
Google Scholar
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(1):10-7
PubMed Web of Science ®Google Scholar
Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006;101(1):120-5
PubMed Web of Science ®Google Scholar
Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111(2 Pt 1):436-47
PubMed Web of Science ®Google Scholar
Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95(3):593-6
PubMed Web of Science ®Google Scholar
Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol 2008;67(3):204-12
PubMedGoogle Scholar
Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94(5):642-6
PubMed Web of Science ®Google Scholar
Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16(1):46-52
PubMedGoogle Scholar
Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;6(1):47-86
PubMedGoogle Scholar
Mariani A, Dowdy SC, Keeney GL, et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004;95(1):120-6
PubMed Web of Science ®Google Scholar
Greven KM, Randall M, Fanning J, et al. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1990;19(3):529-34
PubMed Web of Science ®Google Scholar
Ayhan A, Taskiran C, Celik C, Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 2004;93(1):9-13
PubMedGoogle Scholar
Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol 2005;97(3):820-7
PubMedGoogle Scholar
Mariani A, Webb MJ, Keeney GL, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002;84(3):437-42
PubMedGoogle Scholar
Mariani A, Webb MJ, Keeney GL, et al. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol 2003;89(2):236-42
PubMedGoogle Scholar
Mariani A, Webb MJ, Keeney GL, et al. Hematogenous dissemination in corpus cancer. Gynecol Oncol 2001;80(2):233-8
PubMed Web of Science ®Google Scholar
Mariani A, Webb MJ, Keeney GL, et al. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 2002;87(3):274-80
PubMed Web of Science ®Google Scholar
Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56(4):419-27
PubMed Web of Science ®Google Scholar
Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404-11
PubMed Web of Science ®Google Scholar
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(3):744-51
PubMed Web of Science ®Google Scholar
Lukka H, Chambers A, Fyles A, et al. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. Gynecol Oncol 2006;102(2):361-8
PubMedGoogle Scholar
Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 2007;18(10):1595-604
PubMed Web of Science ®Google Scholar
Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114(11):1313-20
PubMed Web of Science ®Google Scholar
Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373(9658):137-46
PubMed Web of Science ®Google Scholar
Hirai M, Hirono M, Oosaki T, et al. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynaecol Obstet 2002;78(1):37-44
PubMedGoogle Scholar
Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 2004;94(2):333-9
PubMedGoogle Scholar
Kodama J, Seki N, Ojima Y, et al. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol 2007;131(1):76-80
PubMedGoogle Scholar
Takeshima N, Ota T, Omatsu K, et al. Postoperative adjuvant chemotherapy in surgically staged grade 3 endometrial cancer. Anticancer Res 2008;28(3B):1785-8
PubMedGoogle Scholar
Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95(3):266-71
PubMed Web of Science ®Google Scholar
Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108(1):226-33
PubMed Web of Science ®Google Scholar
Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90(1):181-5
PubMed Web of Science ®Google Scholar
Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005;18(1):75-82
PubMed Web of Science ®Google Scholar
Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24(6):797-806
PubMed Web of Science ®Google Scholar
Huh WK, Powell M, Leath CA, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91(3):470-5
PubMed Web of Science ®Google Scholar
Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;105(3):677-82
PubMedGoogle Scholar
Thomas MB, Mariani A, Cliby WA, et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;107(2):186-9
PubMedGoogle Scholar
Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005;98(3):353-9
PubMed Web of Science ®Google Scholar
Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 2009;112(3):558-62
PubMed Web of Science ®Google Scholar
Mcmeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106(1):16-22
PubMed Web of Science ®Google Scholar
Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24(1):36-44
PubMed Web of Science ®Google Scholar
Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007;33(2):177-90
PubMed Web of Science ®Google Scholar
Carey MS, Gawlik C, Fung-Kee-Fung M, et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101(1):158-67
PubMed Web of Science ®Google Scholar
Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18(3):409-20
PubMed Web of Science ®Google Scholar
Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 2008;109(2):250-4
PubMed Web of Science ®Google Scholar
Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15(3):126-35
PubMed Web of Science ®Google Scholar
Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000;2:CD001040
Google Scholar
Urbanski K, Karolewski K, Kojs Z, et al. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 1993;14(Suppl):98-104
PubMedGoogle Scholar
Quinn M. Adjuvant medroxyprogesterone acetate in high risk endometrial cancer. Int J Gynecol Cancer 1998;8(5):387-91
Web of Science ®Google Scholar
Chiva L, Lapuente F, Gonzalez-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008;111(2 Suppl):S101-4
Google Scholar
Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25(19):2798-803
PubMed Web of Science ®Google Scholar
Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001;24(1):43-6
PubMed Web of Science ®Google Scholar
Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 1989;32(1):1-3
PubMed Web of Science ®Google Scholar
Rendina GM, Donadio C, Fabri M, et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1984;17(4):285-91
PubMed Web of Science ®Google Scholar
Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17(6):1736-44
PubMed Web of Science ®Google Scholar
Zhang X, Cao B. Exploration for drug therapy in endometrial carcinoma. Chin Med J (Engl) 1996;109(5):356-60
PubMedGoogle Scholar
Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17(5):964-78
PubMed Web of Science ®Google Scholar
Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103(1):155-9
PubMed Web of Science ®Google Scholar
Lupe K, Kwon J, D'Souza D, et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys 2007;67(1):110-6
PubMed Web of Science ®Google Scholar
Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007;107(2):285-91
PubMed Web of Science ®Google Scholar
Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) {+/-} chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):5503
Google Scholar
Kuoppala T, Maenpaa J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110(2):190-5
PubMed Web of Science ®Google Scholar
Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Curr Opin Oncol 2008;20(5):554-9
PubMedGoogle Scholar
Fujimoto J. Novel therapeutic strategy for uterine endometrial cancers. Int J Clin Oncol 2008;13(5):411-5
PubMedGoogle Scholar
Gadducci A, Tana R, Cosio S, et al. Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol 2008;24(5):239-49
PubMed Web of Science ®Google Scholar
Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112(3):543-52
PubMed Web of Science ®Google Scholar
Daniel AG, Peters WA. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71(4):612-4
PubMed Web of Science ®Google Scholar
Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995;86(1):38-42
PubMed Web of Science ®Google Scholar
Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212(3):711-8
PubMed Web of Science ®Google Scholar
Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008;8:8
PubMedGoogle Scholar
Morice P, Fourchotte V, Sideris L, et al. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005;96(1):245-8
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacotherapy of endometrial cancer

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacotherapy of endometrial cancer

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date